These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 17150005)

  • 1. Urinary albumin excretion and the renin-angiotensin system in cardiovascular risk management.
    Van de Wal RM; Voors AA; Gansevoort RT
    Expert Opin Pharmacother; 2006 Dec; 7(18):2505-20. PubMed ID: 17150005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Albuminuria: a target for treatment of type 2 diabetic nephropathy.
    de Zeeuw D
    Semin Nephrol; 2007 Mar; 27(2):172-81. PubMed ID: 17418686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vasopressin increases urinary albumin excretion in rats and humans: involvement of V2 receptors and the renin-angiotensin system.
    Bardoux P; Bichet DG; Martin H; Gallois Y; Marre M; Arthus MF; Lonergan M; Ruel N; Bouby N; Bankir L
    Nephrol Dial Transplant; 2003 Mar; 18(3):497-506. PubMed ID: 12584270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring and managing urinary albumin excretion: practical advice for primary care clinicians.
    Bakris GL; Kuritzky L
    Postgrad Med; 2009 Jul; 121(4):51-60. PubMed ID: 19641270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microalbuminuria as a risk factor: the influence of renin-angiotensin system blockade.
    Menne J; Chatzikyrkou C; Haller H
    J Hypertens; 2010 Oct; 28(10):1983-94. PubMed ID: 20634721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Manidipine treatment in patients with albuminuria not sufficiently reduced with renin-angiotensin system blockers.
    Galceran J; Plana J; Felip A; Pou G; Vila J; Sobrino J
    Expert Rev Cardiovasc Ther; 2010 Jun; 8(6):751-7. PubMed ID: 20528630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic approaches in lowering albuminuria: travels along the renin-angiotensin-aldosterone-system pathway.
    Heerspink HJ
    Adv Chronic Kidney Dis; 2011 Jul; 18(4):290-9. PubMed ID: 21782135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baseline albuminuria predicts the efficacy of blood pressure-lowering drugs in preventing cardiovascular events.
    Boersma C; Postma MJ; Visser ST; Atthobari J; de Jong PE; de Jong-van den Berg LT; Gansevoort RT;
    Br J Clin Pharmacol; 2008 May; 65(5):723-32. PubMed ID: 18241288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microalbuminuria and urinary albumin excretion: French clinical practice guidelines.
    Halimi JM; Hadjadj S; Aboyans V; Allaert FA; Artigou JY; Beaufils M; Berrut G; Fauvel JP; Gin H; Nitenberg A; Renversez JC; Rusch E; Valensi P; Cordonnier D
    Diabetes Metab; 2007 Sep; 33(4):303-9. PubMed ID: 17702622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The evolution of angiotensin blockade in the management of cardiovascular disease.
    Nantel P; René de Cotret P
    Can J Cardiol; 2010 Dec; 26 Suppl E():7E-13E. PubMed ID: 21620285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The future of renin inhibition].
    Uresin AY; Baran E
    Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():32-8. PubMed ID: 20019475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal and cardio-protective effects of direct renin inhibition: a systematic literature review.
    Lambers Heerspink HJ; Perkovic V; de Zeeuw D
    J Hypertens; 2009 Dec; 27(12):2321-31. PubMed ID: 19727007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for a dose effect of renin-angiotensin system inhibition on progression of microalbuminuria in Type 2 diabetes: a meta-analysis.
    Blacklock CL; Hirst JA; Taylor KS; Stevens RJ; Roberts NW; Farmer AJ
    Diabet Med; 2011 Oct; 28(10):1182-7. PubMed ID: 21627686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microalbuminuria and hypertension.
    Reboldi G; Gentile G; Angeli F; Verdecchia P
    Minerva Med; 2005 Aug; 96(4):261-75. PubMed ID: 16179893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent changes in the landscape of combination RAS blockade.
    Epstein BJ; Smith SM; Choksi R
    Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of the Renin-Angiotensin-Aldosterone System and Its Pharmacological Inhibitors in Cardiovascular Diseases: Complex and Critical Issues.
    Borghi C; ; Rossi F;
    High Blood Press Cardiovasc Prev; 2015 Dec; 22(4):429-44. PubMed ID: 26403596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypertension and microalbuminuria: the new detrimental duo.
    Verdecchia P; Reboldi GP
    Blood Press; 2004; 13(4):198-211. PubMed ID: 15581333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Effects of Direct Renin Inhibitor and Angiotensin Receptor Blocker on Albuminuria in Hypertensive Patients with Type 2 Diabetes. A Randomized Controlled Trial.
    Uzu T; Araki SI; Kashiwagi A; Haneda M; Koya D; Yokoyama H; Kida Y; Ikebuchi M; Nakamura T; Nishimura M; Takahara N; Obata T; Omichi N; Sakamoto K; Shingu R; Taki H; Nagai Y; Tokuda H; Kitada M; Misawa M; Nishiyama A; Kobori H; Maegawa H;
    PLoS One; 2016; 11(12):e0164936. PubMed ID: 28033332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different patterns of one-year evolution of microalbuminuria in hypertensive patients treated with different inhibitors of the renin-angiotensin system.
    Cotter J; Oliveira P; Cunha P; Polónia J
    Rev Port Cardiol; 2008 Nov; 27(11):1395-404. PubMed ID: 19227807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.